Pursuant to Regulation 13(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Nectar Lifesciences has informed about the Statement of Investor Complaints for the Quarter ended December 31, 2017.
The above information is a part of company’s filings submitted to BSE.